SPR Therapeutics presented data at the American Society of Pain & Neuroscience (ASPN) Annual Conference demonstrating the effectiveness of their SPRINT Peripheral Nerve Stimulation (PNS) System for various chronic pain conditions, including postoperative knee pain, migraines, and low back pain. The presentations included results from several studies, highlighting significant pain reduction and improved function for patients. The company emphasized the system’s 60-day treatment duration and minimally invasive nature as key differentiators.
These findings are potentially impactful for patients suffering from chronic pain, offering a non-opioid and non-surgical alternative. The data on chronic postoperative knee pain, a common and often debilitating condition, is particularly noteworthy as it suggests a solution for patients who don’t find relief with traditional treatments. The research on migraine pain also represents a significant advancement, as it’s the first study to examine PNS effectiveness for this condition. This offers hope for patients who struggle with chronic headaches and migraines, potentially improving their quality of life and reducing reliance on medication.
Across multiple studies, the SPRINT PNS System consistently demonstrated substantial pain relief (≥50%) in a significant proportion of participants. In the randomized controlled trial for chronic low back pain, SPRINT PNS outperformed standard interventional management at both three and six months post-treatment. The data from the studies on occipital head pain showed sustained pain relief and functional improvements even 12 months after treatment. While the most common side effect was skin irritation, there were no serious or unanticipated adverse events related to the treatment in the postoperative knee pain study. Two infections were reported at lead exit sites in one of the occipital head pain studies, both of which resolved with antibiotics.
This body of evidence further strengthens the position of SPRINT PNS as a viable treatment option for a variety of chronic pain conditions. The positive long-term outcomes observed in several studies suggest that this technology may provide durable relief, potentially reducing the need for ongoing interventions. These results could lead to broader adoption of PNS therapy and pave the way for further research into its application for other pain conditions. This offers a promising outlook for both patients and the pain management field as a whole.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
